This section includes the European Medicines Agency's guidelines on the quality of medicines.
The Agency's Committee for Medicinal Products for Human Use (CHMP) prepares scientific guidelines in consultation with regulatory authorities in the European Union (EU) Member States, to help applicants prepare marketing authorisation applications for human medicines.
Guidelines reflect a harmonised approach of the EU Member States and the Agency on how to interpret and apply the requirements for the demonstration of quality, safety and efficacy set outin the Community directives.
The Agency strongly encourages applicants and marketing-authorisation holders to follow these guidelines. Applicants need to justify deviations from guidelines fully in their applications at the time of submission. Before that, they should seek scientific advice, to discuss any proposed deviations during medicine development.
Quality guidelines are provided for:
- Active substance
- Specifications, analytical procedures and analytical validation
- Pharmaceutical development
- Specific types of products
- Post-approval change management protocols
For the quality guidelines on biological medicines and materials of animal and/or human origin, please refer to the biologicals section.
How useful is this page?
Average rating:Based on 12 ratings
Add your rating:
- See all ratings
2 ratings0 ratings2 ratings1 ratings7 ratings